drugset / Trial / NCT02242292

Study to Evaluate Efficacy and Safety of Oral Doses of Hyoscine Butylbromide for the Treatment of Occasional Abdominal Pain, Cramping, and Discomfort

NCT02242292

Phase 2 Completed 527 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

Study to determine whether hyoscine butylbromide can provide adequate symptomatic relief of a single episode - defined as lasting not longer than 1 day - and multiple episodes of abdominal pain or discomfort associated with cramping when used as needed

Timeline

Start
2006-04
Primary completion
2007-01
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Hyoscine butylbromide Unknown 20 mg Oral

Indications

No indication recorded.